Logo

Novartis' Beovu (brolucizumab) Receives FDA's Approval for the Treatment of Wet Age-Related Macular Degeneration

Share this

Novartis' Beovu (brolucizumab) Receives FDA's Approval for the Treatment of Wet Age-Related Macular Degeneration

Shots:

  • The approval is based on P-III HAWK (NCT02307682) & HARRIER (NCT02434328) studies involves assessing of Beovu (intravitreal injection)- 6mg (HAWK and HARRIER) & 3mg (HAWK) vs Aflibercept (2mg) in 1-800+ patients with wet AMD across 400 centers globally
  • The P-III studies demonstrated non-inferiority in mean change BCVA @1yr. (week 48); reductions in central subfield thickness- @1yr. 56% & 51% maintained on the 3mos. dosing interval
  • Beovu (RTH258) is the only anti-VEGF in wet AMD recommended to maintain eligible patients on up to 3mos. dosing intervals immediately after loading phase with no compromise in efficacy

Click here to­ read full press release/ article | Ref: Novartis | Image: Financial times


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions